• Position-3 GnRH Antagonists: Synthesis and Activity

  2026-10-01

  Samant and colleagues examined how replacing the position-3 residue of degarelix with stereoisomeric 3-(2-methoxy-5-pyridyl)-alanine affected GnRH receptor antagonism and duration of action. The D-isomer preserved strong in vitro potency, whereas the L-isomer was substantially weaker, and both analogs were short-acting in the castrated-male-rat assay.

• GnRH Antagonists with 2-OMe-5Pal at Position 3

  2026-10-01

  Samant and colleagues investigated how replacing position 3 of degarelix with D- or L-3-(2-methoxy-5-pyridyl)-alanine changes GnRH receptor antagonism and in vivo persistence. The D-isomer retained strong in vitro activity, whereas the L-isomer was weaker, and both analogs were short-acting in castrated male rats, separating receptor potency from pharmacokinetic duration.

• Tigecycline Workflows for Resistant-Pathogen Research

  2026-09-30

  Build stronger resistant-pathogen assays with Tigecycline, a glycylcycline antibiotic that links 30S ribosomal inhibition to isolate-specific susceptibility testing. This guide translates carbapenemase-transmission findings into practical workflows for MRSA, GISA, Enterobacterales, and plasmid-resistance studies while separating evidence-backed observations from optimization starting points.

• SN-38 Disrupts FUBP1–FUSE DNA Binding

  2026-09-30

  The reference study identifies camptothecin and its active metabolite SN-38 as inhibitors of the FUBP1–FUSE DNA interaction, adding a transcriptional mechanism to their established topoisomerase I activity. Its combination of biochemical screening and hepatocellular carcinoma cell analyses provides a framework for separating direct disruption of oncogenic DNA regulation from downstream replication stress and apoptosis.

• N1-Methyl-Pseudouridine-5'-Triphosphate Workflow

  2026-09-29

  Build more stable, efficiently translated RNA for mechanistic studies, co-formulated mRNA experiments, and vaccine-development workflows with N1-Methyl-Pseudouridine-5'-Triphosphate. This practical guide connects reagent handling and in vitro transcription optimization to the co-encapsulated antigen–adjuvant mRNA strategy reported in influenza research.

• Thiothixene: From D2 Blockade to Efferocytosis

  2026-09-29

  Thiothixene is a typical antipsychotic agent with an emerging macrophage biology: it enhances continual efferocytosis through Stra6L, vitamin A signaling, and Arginase 1. This article translates the pivotal findings into practical assay-design decisions while separating established pharmacology from early translational opportunities.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-28

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin reagent for detecting α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell and tissue samples. It supports cell surface carbohydrate detection, immunofluorescence staining, and flow cytometry, but it is not a general membrane stain, antibody substitute, or probe for non-carbohydrate targets.

• Preserving DFCP1–ATGL Evidence After Lysis

  2026-09-28

  DFCP1 changes how researchers interpret ATGL-driven lipid droplet breakdown during starvation. This article connects that mechanism to practical sample-preparation decisions, showing where a broad-spectrum Protease Inhibitor Cocktail can protect extracted proteins—and where EDTA or inhibitor carryover may complicate downstream assays.

• PBA-Modified PAD4 Inhibitors Suppress Tumor NETs

  2026-09-27

  The study reports a phenylboronic acid-modified PAD4 inhibitor, 5i, designed to favor tumor-associated uptake while suppressing the neutrophil PAD4–H3cit–NET pathway. In mouse tumor models, the compound reduced tumor growth and metastasis, supporting targeted PAD4 inhibition as a research direction while leaving important questions about delivery, mechanism, and clinical translation.

• Sulfaphenazole Restores Perfusion in Skin Injury

  2026-09-26

  In a mouse model of repeated ischemia–reperfusion injury, sulfaphenazole rapidly restored wound-region perfusion and reduced pressure-injury severity, with improvements in closure, tensile strength, hypoxia, inflammation, and fibrosis. The findings support vascular recovery as a therapeutic target, while further work is needed to establish dosing, mechanism, and relevance to human wounds.

• Resazurin Cell Viability Assay: Reading Redox Signals

  2026-09-25

  The Resazurin Cell Viability Assay Kit turns cellular reducing activity into a sensitive viability readout. Using parthenolide-treated lymphoid malignancy models as a case study, this article explains how to interpret metabolic signals without mistaking them for direct evidence of cell death or mechanism.

• Aurora A Overexpression in High-Risk Retinoblastoma

  2026-09-25

  A 2024 study links elevated Aurora kinase A (AURKA) in human retinoblastoma to histopathologic features associated with high risk, and combines patient-tissue analysis with functional models to examine its relevance. The findings support further investigation of AURKA as a target, while leaving clinical benefit, biomarker performance, and ocular delivery unresolved.

• PreScission Protease for Tag-Free Protein Workflows

  2026-09-24

  PreScission Protease (PSP) enables sequence-directed affinity-tag removal under cold conditions, making it useful when a purified fusion protein must be converted into a cleaner substrate for downstream assays. This guide connects practical cleavage optimization with research on Drosophila Keap1 and nuclear architecture—while distinguishing assay-planning ideas from experiments actually reported in the study.

• Wnt agonist 1: Practical Pathway Workflows

  2026-09-24

  Use Wnt agonist 1 (BML-284) as a controlled gain-of-function probe for canonical Wnt/TCF signaling, differentiation studies, and carefully designed pathway-to-phenotype experiments. This guide connects practical dosing and troubleshooting with a lung cancer brain-metastasis study while distinguishing what the paper demonstrated from what a new experiment must test.

• TaCRVP Rewires Tomato Catalase to Suppress Defense

  2026-09-23

  The study identifies TaCRVP, a secreted protein from Tuta absoluta oral secretions, as an effector that targets tomato catalase SlCAT2. By increasing SlCAT2 activity and stability, TaCRVP suppresses hydrogen peroxide signaling and downstream defenses, revealing a two-part strategy for manipulating plant redox homeostasis during herbivory.

8009 records 1/534 page Next 12345 下5页 Last page